"Drugs on oxygen": An update and perspective on the role of cytochrome P450 testing in pharmacology

Expert Opinion on Drug Metabolism and Toxicology

Volumn 8, Issue 11, 2012, Pages 1357-1362

  Tralau, Tewes ^a   Luch, Andreas ^a  

^a FEDERAL INSTITUTE FOR RISK ASSESSMENT   (Germany)

Author keywords

CYP screening; Cytochrome P450 dependent metabolism; Drug testing; Drugdrug interaction (DDI); in vitro testing

Indexed keywords

CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4;

BINDING AFFINITY; CELL TRANSPORT; COMPETITIVE INHIBITION; DRUG BLOOD LEVEL; DRUG DEVELOPMENT; DRUG INDUSTRY; DRUG INTERACTION; DRUG METABOLISM; DRUG TOXICITY; DRUG TRANSFORMATION; DRUG TRANSPORT; ELECTROPHILICITY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME METABOLISM; ENZYME SPECIFICITY; FIRST PASS EFFECT; GENETIC VARIABILITY; GENOTYPE; HIGH THROUGHPUT SCREENING; PHARMACOKINETICS; PHARMACOLOGY; POLYPHARMACY; PROTEIN SYNTHESIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; STANDARDIZATION; TRANSCRIPTION INITIATION; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; DRUG TOXICITY; HUMANS; OXIDATION-REDUCTION; OXYGEN; PHARMACEUTICAL PREPARATIONS; XENOBIOTICS;

EID: 84867505906     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2012.722620     Document Type: Review

References (48)

1. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3(8):711-16
2. Quinney SK, Zhang X, Lucksiri A, et al. Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin. Drug Metab Dispos 2010;38(2):241-8
3. Galetin A, Gertz M, Houston JB. Potential role of intestinal first-pass metabolism in the prediction of drug-drug interactions. Expert Opin Drug Metab Toxicol 2008;4(7):909-22
4. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol 2008;21(1):70-83
5. Shi S, Klotz U. Drug interactions with herbal medicines. Clin Pharmacokinet 2012;51(2):77-104
6. Rodriguez-Fragoso L, Martinez-Arismendi JL, Orozco-Bustos D, et al. Potential risks resulting from fruit/vegetable-drug interactions: Effects on drug-metabolizing enzymes and drug transporters. J Food Sci 2011;76(4):R112-24
7. Choi JS, Piao YJ, Kang KW. Effects of quercetin on the bioavailability of doxorubicin in rats: Role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res 2011;34(4):607-13
8. Guengerich FP. Mechanisms of drug toxicity and relevance to pharmaceutical development. Drug Metab Pharmacokinet 2011;26(1):3-14
9. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. Clin Pharmacokinet 2009;48(11):689-723
10. Donato MT, Lahoz A, Castell JV, Gomez-Lechon MJ. Cell lines: A tool for in vitro drug metabolism studies. Curr Drug Metabol 2008;9(1):1-11
11. Landsiedel R, Fabian E, Tralau T, Luch A. Chemical toxicity testing in vitro using cytochrome P450-expressing cell lines, such as human CYP1B1. Nat Protocols 2011;6(5):677-88
12. Tolosa L, Pinto S, Donato MT, et al. Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs. Toxicol Sci 2012;127(1):187-98
13. Tralau T, Luch A. Drug-mediated toxicity: Illuminating the 'bad' in the test tube by means of cellular assays? Trends Pharmacol Sci 2012;33(7):353-64
14. Yoshizato K, Tateno C, Utoh R. Mice with liver composed of human hepatocytes as an animal model for drug testing. Curr Drug Discov Technol 2012;9(1):63-76
15. Foti RS, Wahlstrom JL. Prediction of CYP-mediated drug interactions in vivo using in vitro data. IDrugs 2008;11(12):900-5
16. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet 2003;42(13):1141-60
17. Darwich AS, Neuhoff S, Jamei M, Rostami-Hodjegan A. Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: A simulation assessment using the "Advanced Dissolution, Absorption, Metabolism (ADAM)" model. Curr Drug Metabol 2010;11(9):716-29
18. le Bourdonnec B, Leister LK. Medicinal chemistry strategies to reduce CYP2D6 inhibitory activity of lead candidates. Curr Med Chem 2009;16(24):3093-121
19. van Schaik RH. Cancer treatment and pharmacogenetics of cytochrome P450 enzymes. Invest New Drugs 2005;23(6):513-22
20. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol 2012;8(3):371-82
21. Shimada T, Tanaka K, Takenaka S, et al. Structure-function relationships of inhibition of human cytochromes P450 1A1, 1A2, 1B1, 2C9, and 3A4 by 33 flavonoid derivatives. Chem Res Toxicol 2010;23(12):1921-35
22. Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metabol 2011;12(7):601-10
23. U.S. Food and Drug Administration. Guidance for Industry, drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. 2006
24. European Medicines Agency. Guideline on the investigation of drug interactions. 2010
25. Foti RS, Wienkers LC, Wahlstrom JL. Application of cytochrome P450 drug interaction screening in drug discovery. Comb Chem High Throughput Screen 2010;13(2):145-58
26. Khuu DN, Scheers I, Ehnert S, et al. In vitro differentiated adult human liver progenitor cells display mature hepatic metabolic functions: A potential tool for in vitro pharmacotoxicological testing. Cell Transplant 2011;20(2):287-302
27. Zientek M, Miller H, Smith D, et al. Development of an in vitro drug-drug interaction assay to simultaneously monitor five cytochrome P450 isoforms and performance assessment using drug library compounds. J Pharmacol Toxicol Methods 2008;58(3):206-14
28. Miller VP, Stresser DM, Blanchard AP, et al. Fluorometric high-throughput screening for inhibitors of cytochrome P450. Ann NY Acad Sci 2000;919:26-32
29. Wu X, Wang J, Tan L, et al. In vitro ADME profiling using high-throughput rapidfire mass spectrometry: Cytochrome P450 inhibition and metabolic stability assays. J Biomol Screen 2012;17(6):761-72
30. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 2010;38(6):981-7
31. Grimm SW, Einolf HJ, Hall SD, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: A perspective of the pharmaceutical research and manufacturers of America. Drug Metab Dispos 2009;37(7):1355-70
32. Lutz JD, Isoherranen N. In vitro to in vivo predictions of drug-drug interactions involving multiple reversible inhibitors. Expert Opin Drug Metab Toxicol 2012;8(4):449-66
33. Nath A, Zientek MA, Burke BJ, et al. Quantifying and predicting the promiscuity and isoform specificity of small-molecule cytochrome P450 inhibitors. Drug Metab Dispos 2010;38(12):2195-203
34. Cheng J, Ma X, Krausz KW, et al. Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity. Drug Metab Dispos 2009;37(8):1611-21
35. Sinz M, Wallace G, Sahi J. Current industrial practices in assessing CYP450 enzyme induction: Preclinical and clinical. AAPS J 2008;10(2):391-400
36. Braeuning A, Kohle C, Buchmann A, Schwarz M. Coordinate regulation of cytochrome P450 1a1 expression in mouse liver by the aryl hydrocarbon receptor and the b-catenin pathway. Toxicol Sci 2011;122(1):16-25
37. Lim YP, Huang JD. Interplay of pregnane X receptor with other nuclear receptors on gene regulation. Drug Metab Pharmacokinet 2008;23(1):14-21
38. Dong H, Lin W, Wu J, Chen T. Flavonoids activate pregnane x receptor-mediated CYP3A4 gene expression by inhibiting cyclin-dependent kinases in HepG2 liver carcinoma cells. BMC Biochem 2010;11:23-32
39. Isoherranen N, Hachad H, Yeung CK, Levy RH. Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: Literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 2009;22(2):294-8
40. Bjornsson TD, Callaghan JT, Einolf HJ, et al. The conduct of in vitro and in vivo drug-drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab Dispos 2003;31(7):815-32
41. Kosugi Y, Hirabayashi H, Igari T, et al. Evaluation of cytochrome P450-mediated drug-drug interactions based on the strategies recommended by regulatory authorities. Xenobiotica 2012;42(2):127-38
42. Williams PA, Cosme J, Ward A, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003;424(6947):464-8
43. Roy K, Roy PP. QSAR of cytochrome inhibitors. Expert Opin Drug Metab Toxicol 2009;5(10):1245-66
44. Chan A, Ng TR, Yap KY. Clinically-relevant anticancer-antidepressant drug interactions. Expert Opin Drug Metab Toxicol 2012;8(2):173-99
45. Zakrzewski-Jakubiak H, Doan J, Lamoureux P, et al. Detection and prevention of drug-drug interactions in the hospitalized elderly: utility of new cytochrome P450-based software. Am J Geriatr Pharmacother 2011;9(6):461-70
46. Ajayi F, Sun H, Perry J. Adverse drug reactions: A review of relevant factors. J Clin Pharmacol 2000;40(10):1093-101
47. Ag-undez JA, Lucena MI, Martinez C, et al. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol 2011;7(7):817-28
48. Kidambi S, Yarmush RS, Novik E, et al. Oxygen-mediated enhancement of primary hepatocyte metabolism, functional polarization, gene expression, and drug clearance. Proc Natl Acad Sci USA 2009;106(37):15714-19